Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
| EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
|---|---|---|---|---|
| Only notified under the "contained use" procedure. Dossier submitted on . | EXACT 2 is a randomized, multicenter, double-blind, placebo-controlled Phase 2b trial designed to evaluate the safety, feasibility, and efficacy of percutaneous endovascular catheter-facilitated intramyocardial administration of XC001 in patients with ref | XyloCor Therapeutics | Humans | VEGF |
| B/BE/07/BVW1 | Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis | ActoGeniX N.V. | Humans | Gene coding for the human interleukin-10 (hIL-10) |
| Only notified under the "contained use" procedure. Dossier submitted on . | Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system | Sandoz Pharma, LTD | Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR) |